Recent Innovative Approaches to Intensify the Efficacy and Safety of CAR-T Cell Therapy in Cancers
Author:
Publisher
Springer International Publishing
Link
https://link.springer.com/content/pdf/10.1007/16833_2022_64
Reference166 articles.
1. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396:839–852
2. Anampa J, Chen A, Wright J, Patel M, Pellegrino C, Fehn K, Sparano JA, Andreopoulou E (2018) Phase I trial of Veliparib, a poly ADP ribose polymerase inhibitor, plus metronomic cyclophosphamide in metastatic HER2-negative breast cancer. Clin Breast Cancer 18:e135–e142
3. Anurathapan U, Chan RC, Hindi HF, Mucharla R, Bajgain P, Hayes BC, Fisher WE, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF (2014) Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther 22:623–633
4. Avigan D, Rosenblatt J (2018) Vaccine therapy in hematologic malignancies. Blood 131:2640–2650
5. Bach PB, Giralt SA, Saltz LB (2017) FDA approval of Tisagenlecleucel: promise and complexities of a $475 000 cancer drug. JAMA 318:1861–1862
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies;Medical Oncology;2023-04-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3